7780 — Daiken Biomedical Co Share Price
Last trade - 00:00- TWD12.51bn
- TWD11.32bn
- TWD1.36bn
- 55
- 21
- 50
- 36
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 11.3 | ||
| Price to Tang. Book | 11.36 | ||
| Price to Free Cashflow | 58.34 | ||
| Price to Sales | 7.69 | ||
| EV to EBITDA | 47.85 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 20.82% | ||
| Return on Equity | 20.95% | ||
| Operating Margin | 14.17% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | TWDm | n/a | n/a | 884.97 | 1,190.41 | 1,362.39 | n/a | n/a | 24.08% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | +77.83 | -33.54 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Daiken Biomedical Co Ltd is a Taiwan-based company mainly engaged in the research, development and sales of health food. The Company's main products include fish oil, lutein, maca, bitter melon peptide cinnamon capsules, women's probiotics, good sleep sesamin, high dietary fiber powder packets, and others. The Company's sales channels are not only through the official website of Daiyan, but also through online channels such as momo, Shopee, PChome, and physical channels including Watsons, FamilyMart, and Cosmetics. The Company mainly operates in the Taiwan market.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- June 30th, 2025
- Incorporated
- June 20th, 2018
- Public Since
- October 28th, 2024
- Sector
- Food & Tobacco
- Industry
- Consumer Defensives
- Exchange
- Taiwan Stock Exchange
- Shares in Issue
- 60,002,000
- Address
- 12F, No.37, Section 2, TAIPEI, 106
- Web
- https://www.daikenshop.com/
- Phone
- +886 800000028
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for 7780
Similar to 7780
AGV Products
Taiwan Stock Exchange
Charoen Pokphand Enterprise Taiwan Co
Taiwan Stock Exchange
Dawushan Farm Technology Co
Taiwan Stock Exchange
Formosa Oilseed Processing Co
Taiwan Stock Exchange
Fwusow Industry Co
Taiwan Stock Exchange
FAQ
As of Today at 20:08 UTC, shares in Daiken Biomedical Co are trading at TWD208.50. This share price information is delayed by 15 minutes.
Shares in Daiken Biomedical Co last closed at TWD208.50 and the price had moved by over the past 365 days. In terms of relative price strength the Daiken Biomedical Co share price has matched the FTSE Developed Asia Pacific Index by over the past year.
There is no consensus recommendation for this security.
Find out moreThe Daiken Biomedical Co dividend yield is 4.16% based on the trailing twelve month period.
Last year, Daiken Biomedical Co paid a total dividend of TWD8.68, and it currently has a trailing dividend yield of 4.16%.Looking ahead, the next dividend pay date is 2025-09-15.
We do not have data on when Daiken Biomedical Co is to next pay dividends. The historic dividend yield on Daiken Biomedical Co shares is currently 4.16%.
To buy shares in Daiken Biomedical Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of TWD208.50, shares in Daiken Biomedical Co had a market capitalisation of TWD12.51bn.
Here are the trading details for Daiken Biomedical Co:
- Country of listing: Taiwan
- Exchange: TAI
- Ticker Symbol: 7780
Based on an overall assessment of its quality, value and momentum Daiken Biomedical Co is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Daiken Biomedical Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -0.96%.
As of the last closing price of TWD208.50, shares in Daiken Biomedical Co were trading +1.5% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Daiken Biomedical Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at TWD208.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Daiken Biomedical Co's directors